Ask the Pharmacist Question: What steps can I take to improve absorption of acalabrutinib. I had a total gastrectomy in 1974 and a Roux en Y in 2005, so my compromised
Ask the Pharmacist Question: Are there any side effects of dysphasia or esophageal spasm when taking acalabrutinib? I began this treatment 9/1/2021 and these effects began 2-3 weeks ago. I have
This video was recorded at the 62nd Annual Meeting of the American Society of Hematology, held virtually in December 2020. Dr. Davids specializes in CLL and serves on the CLL Society’s Medical Advisory Board.
In this interview, our own Dr. Brian Koffman spoke with Dr. Neil Kay, a Professor of Medicine and a hematologist at Mayo Clinic, and Dr. Sameer Parikh, a hematologist, an oncologist at the Mayo Clinic in Rochester, MN. They discussed why early-stage patients usually do not receive treatment and how that paradigm may be changing with the availability of new targeted therapies and better prognostic markers.
At the annual meeting of the American Society of Clinical Oncology (ASCO) 2021, our own Dr. Brian Koffman interviewed Dr. Matthew Davids, Associate Director of the Center for Chronic Lymphocytic Leukemia (CLL) at Dana-Farber Cancer Institute in Boston, MA. They discussed new data from the ELEVATE R/R study, which is comparing acalabrutinib with ibrutinib head-to-head in high-risk patients with relapsed/refractory CLL and del(17p) or del(11q).
While hardly groundbreaking, the four-year follow-up data of the ELEVATE-TN trial affirms our confidence that acalabrutinib is a strong choice for frontline therapy in CLL.
Does the increased selectivity of the Bruton tyrosine kinase inhibitor (BTKi) acalabrutinib (Aca) compared to ibrutinib (Ib) improve tolerability while maintaining efficacy?
There has been much excitement about the possibility that BTK inhibitors such as ibrutinib or acalabrutinib might improve outcomes in COVID-19 for all patients ever since Dr. Treon published a retrospective
An ongoing phase 2 clinical trial is evaluating the efficacy and tolerability of fixed-duration zanubrutinib plus venetoclax for relapsed / refractory CLL.
